Cargando…

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

BACKGROUND: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smets, Ide, Versteegh, Matthijs, Huygens, Simone, Corsten, Cato, Wokke, Beatrijs, Smolders, Joost
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387699/ https://www.ncbi.nlm.nih.gov/pubmed/37529628 http://dx.doi.org/10.1177/20552173231189398

Ejemplares similares

Should anti-CD20 be used as an immune reconstitution therapy?
por: Smets, Ide, et al.
Publicado: (2022)

Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment
por: Bruijstens, Arlette L, et al.
Publicado: (2020)

Distinct Effector Programs of Brain-Homing CD8(+) T Cells in Multiple Sclerosis
por: Koetzier, Steven C., et al.
Publicado: (2022)

Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
por: Blok, Katelijn M., et al.
Publicado: (2023)

Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
por: Huygens, Simone A., et al.
Publicado: (2021)

Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses
por: Janssen, Malou, et al.
Publicado: (2020)

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
por: Cloosterman, Sonja, et al.
Publicado: (2021)

Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine
por: Vellekoop, Heleen, et al.
Publicado: (2021)

Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis
por: Brockington, Alice, et al.
Publicado: (2007)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis
por: Versteegh, Matthijs
Publicado: (2016)

Vitamin D and Multiple Sclerosis: Correlation, Causality, and Controversy
por: Smolders, Joost
Publicado: (2010)

Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2023)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
por: Perrone, Valentina, et al.
Publicado: (2022)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Distributional consequences of including survivor costs in economic evaluations
por: Kellerborg, Klas, et al.
Publicado: (2021)

Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis
por: Smets, Ide, et al.
Publicado: (2021)

Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
por: Caster, Ola, et al.
Publicado: (2015)

Lymphopenia in treatment-naive relapsing multiple sclerosis
por: Lim, Zhi Wei, et al.
Publicado: (2016)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Smoking at time of CIS increases the risk of clinically definite multiple sclerosis
por: van der Vuurst de Vries, Roos M., et al.
Publicado: (2018)

Exploring the effect of vitamin D(3) supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis
por: Rolf, Linda, et al.
Publicado: (2017)

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients
por: Calocer, Floriane, et al.
Publicado: (2018)

Programmed Cell Death Protein 1–Positive CD8(+) T Cells in Multiple Sclerosis: Exhausted Fighters or Peacekeepers
por: Smolders, Joost, et al.
Publicado: (2022)

An Update on Vitamin D and Disease Activity in Multiple Sclerosis
por: Smolders, Joost, et al.
Publicado: (2019)

Editorial: Environmental factors influencing the immune functions during multiple sclerosis
por: Smolders, Joost, et al.
Publicado: (2023)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
por: Polak, Tobias B, et al.
Publicado: (2022)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
por: Fronza, Marzia, et al.
Publicado: (2021)

Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
por: Habek, Mario, et al.
Publicado: (2022)

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options
por: Koleva-Kolarova, Rositsa, et al.
Publicado: (2022)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

T-cell surveillance of the human brain in health and multiple sclerosis
por: Smolders, Joost, et al.
Publicado: (2022)

Multiple sclerosis: why we should focus on both sides of the (auto) antibody
por: den Dunnen, Jeroen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gn75olf0agmhg1l3266ve2rak9